ADMIRENCT06456554
Acellular Dermal Matrix Investigation in Breast Reconstruction
At risk: Primary completion moved at least 11 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 17 versions: 17 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Dec 2026 to Dec 2027
- Eligibility criteria expanded, about 21 words
- Site details revised at 2 of 13 sites
- Minor Trial sites expanded: 10 → 13 locationsv16
- Minor Study sites revised (10)v15
- Notable Eligibility criteria shortened, about 7 words
- Study sites revised (10)
- Minor Study sites: 7 to 10v13
Show 11 earlier versionsHide 11 earlier versions
- Minor Study sites: 6 to 7v12
- Minor Study sites: 4 to 6v11
- Minor Study sites: 3 to 4v10
- Notable Eligibility criteria expanded, about 2 words
- Collaborators: 2 to 1
- Minor Start date changed from estimate of Oct 2024 to Nov 22, 2024v8
- Minor Site details revised at 1 of 3 sitesv7
- Minor Study sites: 2 to 3v6
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 1 to 2
- Start date: Sep 2024 to Oct 2024
- Minor Study sites: 0 to 1v4
- Minor Start date: Aug 2024 to Sep 2024v3
- Notable Phase: Phase 3 to Not applicablev2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Rate of major adverse events
Timeframe: 12 months
Health related quality of life
Timeframe: 12 months
Secondary (4)
Change in quality of life
Procedure related adverse events
Investigational device related adverse events
Histopathology assessment
Arms and interventions
Acellular Dermal MatrixExperimental
Breast reconstruction with Cortiva Tissue Matrix
no Acellular Dermal MatrixNo intervention
Breast reconstruction only with no ADM
Devices: Acellular Dermal Matrix (Cortiva Tissue Matrix)
Sites
13 sites in 1 country